Aravind Asokan Ph.D. is a professor and director of gene therapy in the department of surgery at Duke University School of Medicine.
Aravind has published widely on AAV biology and vector development and has made significant contributions towards structure-guided engineering of viruses for therapeutic gene transfer applications. His lab’s work has contributed to a variety of translational efforts using AAV gene therapy in genetic disorders such as muscular dystrophy, cardiac failure and neuropathies. He is also a founder of StrideBio, a gene therapy company developing novel AAV vector technologies and also served as a scientific co-founder of Bamboo Therapeutics (later acquired by Pfizer).
He received undergraduate degrees from the Birla Institute of Technology and Science and his doctorate in pharmaceutical chemistry from the University of North Carolina.